Affimed
AFMD

$5.12

0.39%

Market Cap: 78M

About: Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

Employees: 78

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 6 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

400% more call options, than puts

Call options by funds: $5K | Put options by funds: $1K

12.57% less ownership

Funds ownership: 30.71% [Q4 2023] → 18.14% (-12.57%) [Q1 2024]

36% less funds holding

Funds holding: 67 [Q4 2023] → 43 (-24) [Q1 2024]

50% less capital invested

Capital invested by funds: $28.7M [Q4 2023] → $14.4M (-$14.3M) [Q1 2024]

92% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 26

100% less funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 0 (-1) [Q1 2024]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 41

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$5

2%

downside

Avg. target

$14.17

177%

upside

High target

$25

388%

upside

6 analyst ratings

5 positive

83%

1 neutral

17%

0 negative

0%

Laidlaw & Co. Yale Jen	388%upside $25	Buy Maintained	13 Jun 2024
HC Wainwright & Co. Swayampakula Ramakanth	95%upside $10	Buy Reiterated	13 Jun 2024
HC Wainwright & Co. Swayampakula Ramakanth	95%upside $10	Buy Reiterated	3 Jun 2024
Wells Fargo Yanan Zhu	388%upside $25	Overweight Maintained	1 Apr 2024
Stifel Bradley Canino	2%downside $5	Hold Maintained	1 Apr 2024

See Analyst Rankings

Financial journalist opinion

Affimed N.V. (AFMD) Q1 2024 Earnings Call Transcript

Affimed N.V. (NASDAQ:AFMD ) Q1 2024 Earnings Conference Call June 12, 2024 8:30 AM ET Company Participants Alexander Fudukidis – Head, IR Andreas Harstrick – CMO and Interim CEO Michael Wolf – VP, Finance Conference Call Participants Srikripa Devarakonda - Truist Securities Daina Graybosch - Leerink Partners Maury Raycroft - Jefferies Li Watsek - Cantor Fitzgerald Yale Jen - Laidlaw & Company Bradley Canino - Stifel, Nicolaus & Company Operator Good day, everyone and welcome to Affimed's First Quarter 2024 Earnings and Corporate Update Call.

Affimed N.V. (AFMD) Q1 2024 Earnings Call Transcript

Affimed Reports First Quarter 2024 Financial Results & Business Update

- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of 7 patients with complete response (CR) -

Affimed Reports First Quarter 2024 Financial Results & Business Update

Affimed: AFM24's Update Was Good, Acimtamig's Should Be Better

Affimed's 06/01/24 update on AFM24 means the company has a second viable commercial asset. This is why the stock popped after ASCO. Acimtamig's update is due before the end of this month. If it is positive, the stock should run again for a possible 3-5x. Although the company will likely raise capital after the announcement, I am comfortable owning shares into the action and I am a fan now for the longer term.

Affimed: AFM24's Update Was Good, Acimtamig's Should Be Better

Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024

MANNHEIM, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2024 results and corporate update on Wednesday, June 12, 2024. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET.

Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024

Zacks Investment Research

Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study

Affimed (AFMD) rallies 69% on positive follow-up efficacy data from its early to mid-stage study of the AFM24/Tecentriq combo therapy to treat heavily-pretreated EGFR wild-type NSCLC patients.

Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study

Zacks Investment Research

Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?

Here is how Affimed N.V. (AFMD) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?

Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort

MANNHEIM, Germany, June 01, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced longer follow-up data from the EGFRwt cohort and initial clinical efficacy data from the EGFRmut cohort from the on-going AFM24-102 study in NSCLC.

Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort

Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer

Efficacy and safety of AFM24 in combination with atezolizumab, a checkpoint inhibitor, is being evaluated in non-small cell lung cancer patients with EGFR wild-type and EGFR mutant advanced/metastatic cancers in the ongoing AFM24-102 phase 1/2a study The FDA's Fast Track designation was granted after its review of the initial efficacy data of the EGFR wild-type cohort from the AFM24-102 study Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need Company to host a conference call / webcast on June 1, 2024 at 7:00 p.m. EDT to discuss the updated data from the AFM24-102 trial MANNHEIM, Germany, May 29, 2024 (GLOBE NEWSWIRE) -- Affimed N.V.

Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer

Affimed Announces Annual General Meeting of Shareholders

MANNHEIM, Germany, May 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2024 Annual General Meeting of Shareholders (the “Annual Meeting”) will be held on June 26, 2024 at 09:00 a.m. CET at the offices of De Brauw Blackstone Westbroek N.V., Burgerweeshuispad 201, 1076 GR Amsterdam, the Netherlands.

Affimed Announces Annual General Meeting of Shareholders

7 Penny Biotech Stocks to Triple Your Investment

One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks.

7 Penny Biotech Stocks to Triple Your Investment

See News Rankings